SF2312 is a natural phosphonate inhibitor of enolase

Nature Chemical Biology

Volumn 12, Issue 12, 2016, Pages 1053-1058

  Leonard, Paul G ^a   Satani, Nikunj ^a   Maxwell, David ^a   Lin, Yu Hsi ^a   Hammoudi, Naima ^a   Peng, Zhenghong ^b   Pisaneschi, Federica ^a   Link, Todd M ^a   Lee, Gilbert R ^a   Sun, Duoli ^a   Prasad, Basvoju A Bhanu ^a   Di Francesco, Maria Emilia ^a   Czako, Barbara ^a   Asara, John M ^c   Wang, Y Alan ^a   Bornmann, William ^d   Depinho, Ronald A ^a   Muller, Florian L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Cardtronics Inc   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Bayou Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOLASE; LYASE INHIBITOR; SF2312; UNCLASSIFIED DRUG; (1,5-DIHYDROXY-2-OXOPYRROLIDIN-3-YL)PHOSPHONIC ACID; 2 PYRROLIDONE DERIVATIVE; ENZYME INHIBITOR; PHOSPHONIC ACID DERIVATIVE;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; METABOLISM; MOLECULAR MODEL; STRUCTURE ACTIVITY RELATION;

DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; ORGANOPHOSPHONATES; PHOSPHOPYRUVATE HYDRATASE; PYRROLIDINONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84990931510     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.2195     Document Type: Article

References (37)

1. Fothergill-Gilmore, L. A. & Michels, P. A. Evolution of glycolysis. Prog. Biophys. Mol. Biol. 59, 105-235 (1993).
2. Deutscher, D., Meilijson, I., Kupiec, M. & Ruppin, E. Multiple knockout analysis of genetic robustness in the yeast metabolic network. Nat. Genet. 38, 993-998 (2006).
3. Baba, T. et al. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol. Syst. Biol. 2, 2006. 0008 (2006).
4. Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033 (2009).
5. Muller, F. L. et al. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 488, 337-342 (2012).
6. Poyner, R. R. & Reed, G. H. Structure of the bis divalent cation complex with phosphonoacetohydroxamate at the active site of enolase. Biochemistry 31, 7166-7173 (1992).
7. Anderson, V. E., Weiss, P. M. & Cleland, W. W. Reaction intermediate analogues for enolase. Biochemistry 23, 2779-2786 (1984).
8. Qin, J., Chai, G., Brewer, J. M., Lovelace, L. L. & Lebioda, L. Structures of asymmetric complexes of human neuron specific enolase with resolved substrate and product and an analogous complex with two inhibitors indicate subunit interaction and inhibitor cooperativity. J. Inorg. Biochem. 111, 187-194 (2012).
9. de AS Navarro, M. V. et al. Structural flexibility in Trypanosoma brucei enolase revealed by X-ray crystallography and molecular dynamics. FEBS J. 274, 5077-5089 (2007).
10. Wedekind, J. E., Poyner, R. R., Reed, G. H. & Rayment, I. Chelation of serine 39 to Mg2+ latches a gate at the active site of enolase: structure of the bis(Mg2+) complex of yeast enolase and the intermediate analog phosphonoacetohydroxamate at 2. 1-Å resolution. Biochemistry 33, 9333-9342 (1994).
11. Zhang, E., Hatada, M., Brewer, J. M. & Lebioda, L. Catalytic metal ion binding in enolase: the crystal structure of an enolase-Mn2+-phosphonoacetohydroxamate complex at 2. 4-Å resolution. Biochemistry 33, 6295-6300 (1994).
12. Watanabe, H., Yoshida, J., Tanaka, E., Ito, M., Miyadoh, S. & Shomura, T. Studies on a new phosphonic acid antibiotic, SF-2312. Scientific Reports of Meiji Seika Kaisha 25, 12-17 (1986).
13. Hanaya, T. & Itoh, C. An efficient synthesis of antibiotic SF-2312 (3-dihydroxyphosphoryl-1, 5-dihydroxy-2-pyrrolidone). Heterocycles 82, 1675-1683 (2011).
14. Liu, Y., Jacobs, H. K. & Gopalan, A. S. A new approach to cyclic hydroxamic acids: intramolecular cyclization of N-benzyloxy carbamates with carbon nucleophiles. Tetrahedron 67, 2206-2214 (2011).
15. Martinez Molina, D. et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84-87 (2013).
16. Brewer, J. M. & Wampler, J. E. A differential scanning calorimetric study of the effects of metal ions, substrate/product, substrate analogues and chaotropic anions on the thermal denaturation of yeast enolase 1. Int. J. Biol. Macromol. 28, 213-218 (2001).
17. Zhang, E., Brewer, J. M., Minor, W., Carreira, L. A. & Lebioda, L. Mechanism of enolase: the crystal structure of asymmetric dimer enolase-2-phospho-D-glycerate/enolase-phosphoenolpyruvate at 2. 0 Å resolution. Biochemistry 36, 12526-12534 (1997).
18. Marangos, P. J., Parma, A. M. & Goodwin, F. K. Functional properties of neuronal and glial isoenzymes of brain enolase. J. Neurochem. 31, 727-732 (1978).
19. Muller, F. L., Fletcher-Sananikone, E., Colla, S., Aquilanti, E. & DePinho, R. Collateral gene inactivation biomarkers and targets for cancer therapy. US patent WO2013090732A2 (2013).
20. Dette, G. A., Knothe, H., Schönenbach, B. & Plage, G. Comparative study of fosfomycin activity in Mueller-Hinton media and in tissues. J. Antimicrob. Chemother. 11, 517-524 (1983).
21. Horii, S. et al. Structure of alahopcin (nourseimycin), a new dipeptide antibiotic. J. Antibiot. (Tokyo) 38, 302-311 (1985).
22. Higashide, E., Kanamaru, T., Fukase, H. & Horii, S. Isolation of dealanylalahopcin, a new amino acid, and its biological activity. J. Antibiot. (Tokyo) 38, 296-301 (1985).
23. Gerlt, J. A., Babbitt, P. C. & Rayment, I. Divergent evolution in the enolase superfamily: the interplay of mechanism and specificity. Arch. Biochem. Biophys. 433, 59-70 (2005).
24. Brewer, J. M. Yeast enolase: mechanism of activation by metal ions. CRC Crit. Rev. Biochem. 11, 209-254 (1981).
25. Lee, J. & Kim, S. H. High-throughput T7 LIC vector for introducing C-terminal poly-histidine tags with variable lengths without extra sequences. Protein Expr. Purif. 63, 58-61 (2009).
26. Studier, F. W. Protein production by auto-induction in high-density shaking cultures. Protein Exp. Purif. 41, 207-234 (2005).
27. Battye, T. G., Kontogiannis, L., Johnson, O., Powell, H. R. & Leslie, A. G. iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr. D Biol. Crystallogr. 67, 271-281 (2011).
28. Evans, P. R. & Murshudov, G. N. How good are my data and what is the resolution? Acta Crystallogr. D Biol. Crystallogr. 69, 1204-1214 (2013).
29. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
30. Chai, G. et al. Expression, purification and the 1. 8 angstroms resolution crystal structure of human neuron specific enolase. J. Mol. Biol. 341, 1015-1021 (2004).
31. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
32. Duncan, C. G. et al. Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget 1, 265-277 (2010).
33. Stommel, J. M. et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318, 287-290 (2007).
34. Bady, P. et al. DNA fingerprinting of glioma cell lines and considerations on similarity measurements. Neuro-oncol. 14, 701-711 (2012).
35. Torsvik, A. et al. U-251 revisited: genetic drift and phenotypic consequences of long-term cultures of glioblastoma cells. Cancer Med. 3, 812-824 (2014).
36. Yuan, M., Breitkopf, S. B., Yang, X. & Asara, J. M. A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nat. Protoc. 7, 872-881 (2012).
37. Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656-670 (2012).